What Is Connect Biopharma Holdings Limi (CNTB) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Connect Biopharma Holdings Limi's intrinsic value is estimated at $1.27, suggesting the stock is overvalued at its current price of $2.43. With 8 out of 9 models flagging downside (-47.6% average return), the market may be pricing in unsustainable growth. Notably, PWERM sees the most upside at +8.0% (fair value: $2.62), while Sentiment SOTP is the most conservative at -70.1% ($0.73). The spread between these extremes — +78.1% — reveals how different analytical frameworks can reach starkly different conclusions.
What Do the Models Say About CNTB?
9 of 13 models are currently active for CNTB. Of these, 1 model suggests upside while 8 models suggest overvaluation. The Bayesian DCF estimates CNTB's intrinsic value at $1.10, implying -54.7% downside from the current price. See which stocks rank higher →
How Does CNTB Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, CNTB ranks #172 by Quality of Company score. CirclFi's QOC score of 5.3/10 evaluates 32 fundamental signals. A score of 5.3 reflects mixed fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
Within the Pharmaceutical Preparations space, Connect Biopharma Holdings Limi competes in an environment where biosimilar competition timeline often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.
Is CNTB a Value Trap?
The Value Trap algorithm is not active for CNTB. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
9 of 13 models are active for Connect Biopharma Holdings Limi. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Connect Biopharma Holdings Limi is rated at 5.3/10. This moderate-tier score shows mixed signals across our quality framework with notable weaknesses.
The gap between the most bullish and bearish model spans +78.1% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every CNTB valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across CNTB's 9 active models, average confidence is 25%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad